RTOG-0424

A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas

Principal Investigator

Barbara J. Fisher

Status

Disease Site

Brain [BN] Lower Grade Glioma

Phase

II

Developmental Therapeutics

No

Primary Objective

To compare the 3-year survival of this regimen to the 3-year survival of the EORTC high-risk low-grade glioma population described by Pignatti et al.

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Histologic proof of supratentorial WHO grade II astrocytoma, oligodendroglioma or oligoastrocytoma confirmed by central pathology review prior to registration. Patient must have at least three of the following risk factors:  Age >/= 40;  Largest preoperative diameter of tumor >/= 6 cm;  Tumor crosses midline;  Tumor subtype of astrocytoma (astrocytoma dominant);  Preoperative Neurological Function Status > 1.

Target Accrual

135